Belantamab mafodotin

Therapeutic indications

Belantamab mafodotin is indicated for:

Multiple myeloma - combination treatment with bortezomib and dexamethasone

Population group: only adults (18 years old or older)

Belantamab mafodotin is indicated in adults for the treatment of relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone in patients who have received at least one prior therapy.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2.5 mg/kg once every 3 weeks

Multiple myeloma - combination treatment with pomalidomide and dexamethasone

Population group: only adults (18 years old or older)

Belantamab mafodotin is indicated in adults for the treatment of relapsed or refractory multiple myeloma in combination with pomalidomide and dexamethasone in patients who have received at least one prior therapy including lenalidomide.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

2.5 mg/kg once for 4 weeks and thereafter 1.9 mg/kg administered once every 4 weeks

Contraindications

Belantamab mafodotin is contraindicated in the following cases:

Lactation

< Previous: Overview

Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.